Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02698800 · ClinicalTrials.gov registry record · NA
Blue Blockers at Night and Insomnia Symptoms
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT02698800 is a NA study that has completed, run by Columbia University. The registered enrollment target is 15 participants.
The verdict
NCT02698800, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
Under entrained conditions, humans maintain a consolidated nocturnal sleep episode that coincides with environmental darkness and endogenous melatonin secretion. Various factors, such as artificial light, can compromise this temporal harmony, resulting in sleep disruption. Light is the strongest synchronizer of the circadian clock, with direct inputs via the retinohypothalamic tract to brain centers regulating sleep and circadian rhythms. Evening light exposure can suppress melatonin secretion and worsen sleep. This is critical, since most individuals routinely expose themselves to light before bedtime. The high sensitivity of the circadian system to blue wavelength light indicates that modern light sources such as light-emitting diodes (LED) may have particularly deleterious effects on sleep. It is possible to selectively filter out blue light while maintaining other visible spectra with blue-blocking (BB) lenses. Wearing BB lenses before bedtime may present a simple, affordable, and safe method to improve sleep. None have yet investigated the effects of BB lenses on subjective and objective sleep in insomnia patients, while simultaneously exploring the effects on melatonin secretion.
Interventions
- DEVICE Blue blocking (BB) lenses
- DEVICE Clear lenses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02698800
The ClinicalTrials.gov registry entry for NCT02698800 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blue blocking (BB) lenses is the first listed.
NCT02698800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02698800 about?
NCT02698800 is a clinical study titled "Blue Blockers at Night and Insomnia Symptoms". Under entrained conditions, humans maintain a consolidated nocturnal sleep episode that coincides with environmental darkness and endogenous melatonin secretion. Various factors, such as artificial light, can compromise this temporal harmony, resulting in sleep disruption. Light is the strongest syn...
What is the current status of trial NCT02698800?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2016-03. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02698800?
The interventions under investigation include: Blue blocking (BB) lenses (DEVICE), Clear lenses (DEVICE).
Who is sponsoring clinical trial NCT02698800?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.